Severe, ulcerative, lichenoid mucositis associated with secukinumab

Thompson, Jordan M.; Cohen, Lisa M.; Yang, Cheng‐San; Kroumpouzos, George

doi:10.1016/j.jdcr.2016.07.009

Cited by 33 publications

(28 citation statements)

References 13 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although it has a favorable safety profile, 2 cases of associated oral lichen planus (OLP)/lichenoid mucositis have been recently described. 1 , 2 …”

Section: Introductionmentioning

confidence: 99%

Oral lichenoid reaction in a psoriatic patient treated with secukinumab: A drug-related rather than a class-related adverse event?

et al. 2018

View full text Add to dashboard Cite

“…Although it has a favorable safety profile, 2 cases of associated oral lichen planus (OLP)/lichenoid mucositis have been recently described. 1 , 2 …”

Section: Introductionmentioning

confidence: 99%

Oral lichenoid reaction in a psoriatic patient treated with secukinumab: A drug-related rather than a class-related adverse event?

et al. 2018

View full text Add to dashboard Cite

“…After reviewing the literature, we found 22 cases of anti‐inflammatory BA‐induced AIBD, which are summarized in Table . We identified three additional cases suspicious for the development of AIBD following treatment with such agents as secukinumab, infliximab, and golimumab, which were ultimately excluded due to lack of diagnostic criteria to diagnose a specific AIBD. Figure demonstrates the PRISMA flowchart of studies assessed.…”

Section: Resultsmentioning

confidence: 99%

Autoimmune blistering diseases provoked during the treatment of chronic inflammatory disease with biologic agents: a systematic review

Gibson

Amber

2019

Int J Dermatology

View full text Add to dashboard Cite

Background To investigate the clinical course of autoimmune blistering diseases (AIBDs) following treatment with biologic agents (BAs) for chronic inflammatory diseases.Methods A comprehensive review of available, published literature was performed using PubMed and CINAHL search engines. Diagnostic criteria of AIBD included positive direct immunofluorescence studies and/or positive serology with clinically suggestive features.Results A total of 22 cases of AIBDs provoked by the use of BAs were found. The most commonly implicated agents were tumor necrosis factor-alpha inhibitors (n = 14). The mean age of onset of AIBD was 59.4 years (median 61.5 years, range 31-82). Average time to onset of AIBD following initiation of the suspected BA was 33.7 AE 43.8 weeks (range 3 days to 152 weeks). Psoriasis was the most common associated condition for which the BA was prescribed (n = 11), followed by rheumatoid arthritis (n = 6) and ulcerative colitis (n = 5). Of the 21 cases reporting AIBD outcome, 17 reported remission or complete resolution upon stopping treatment with the involved BA. Four cases reported continued bullae formation without worsening of disease following cessation of the BA or systemic corticosteroids used to treat the AIBD. Five cases rechallenged the patient with the involved BA and four of the five reported recurrence, often with quicker onset and more severe symptoms.Conclusions BAs may be suspected in patients developing AIBD while being treated for chronic inflammatory diseases. A majority of cases resolve upon cessation of the offending agent.

show abstract

“…There is a long list of other drugs considered capable of causing OLRs, but many case reports lack detail in terms of confirmation of the diagnosis by histopathology, or absence of a definite diagnosis by use of imprecise terminology regarding histological findings . Other medications that may be drugs associated with OLRs include lithium carbonate, hepatitis B vaccine, clopidogrel, ribavirin, carbamazepine, risperidone, certolizumab, glimepiride, duloxetine and secukinumab . Most of these medications however have only single or a few case reports associating them with OLRs, although all have had a biopsy or immunofluorescence to determine the diagnosis of oral lichenoid lesion and some have shown that a rechallenge of the culprit medication has resulted in reappearance of the reaction.…”

Section: Drug‐induced Lichenoid Reactionsmentioning

confidence: 99%

“…7 Other medications that may be drugs associated with OLRs include lithium carbonate, 30 hepatitis B vaccine, 31 clopidogrel, 32 ribavirin, 33 carbamazepine, 34 risperidone, 34 certolizumab, 35 glimepiride, 36 duloxetine 37 and secukinumab. 38 Table 1 details drugs associated with lichenoid-like reactions, and is adapted from Fortuna et al 7…”

Section: Introductionmentioning

confidence: 99%

A review and guide to drug‐associated oral adverse effects—Oral mucosal and lichenoid reactions. Part 2

Teoh

Moses

McCullough

2019

J Oral Pathology Medicine

View full text Add to dashboard Cite

Dental practitioners and other health professionals commonly encounter and manage adverse medicine effects that manifest in the orofacial region. Numerous medicines are associated with a variety of oral adverse effects. However, due to lack of awareness and training, these side effects are not always associated with medicine use and are underreported to pharmacovigilance agencies by dentists and other health professionals. This article aims to inform health professionals about the various oral adverse effects that can occur and the most commonly implicated drugs to improve the management, recognition and reporting of adverse drug effects. This article follows on from Part 1; however, the focus here is on lichenoid reactions and oral mucosal disorders including oral aphthous‐like ulceration, mucositis and bullous disorders such as drug‐induced pemphigus, pemphigoid, Stevens‐Johnson syndrome and toxic epidermal necrolysis.

show abstract

Severe, ulcerative, lichenoid mucositis associated with secukinumab

Cited by 33 publications

References 13 publications

Oral lichenoid reaction in a psoriatic patient treated with secukinumab: A drug-related rather than a class-related adverse event?

Oral lichenoid reaction in a psoriatic patient treated with secukinumab: A drug-related rather than a class-related adverse event?

Autoimmune blistering diseases provoked during the treatment of chronic inflammatory disease with biologic agents: a systematic review

A review and guide to drug‐associated oral adverse effects—Oral mucosal and lichenoid reactions. Part 2

Contact Info

Product

Resources

About